The overall goal of the Clinical Oncology Research Career Development Program is to support the intent of the Paul Calabresi Award for Clinical Oncology (K12). The Program fosters interdisciplinary training in clinical and translational oncology therapeutic research for physicians in one of a number of oncology disciplines, including medical, surgical, dermatologic, pediatric, radiation and pathology. By designing a K12 program that brings together these broad disciplines, the Paul Calabresi Scholars themselves form a multidisciplinary group whose collaborations and interactions augment the overall training efforts under the K12 program. Firm core requirements include completion of required and elective course work for a Certificate in Clinical Translational Oncology at CWRU. A basic research effort is a required part of the training program and is linked to the clinical research efforts that include writing and activating a therapeutic clinical protocol and submission of a career development award application. These efforts will result in highly qualified Paul Calabresi scholars capable of independent research in clinical oncology and therapeutics with a team science orientation based in hypothesis testing of important translational questions in the field. The Program brings together strong Internal and External Advisory Committees committed and experienced in the area of clinical translational therapeutics research in oncology. The Program and the cancer center provides scholars with an outstanding environment to pursue career development. Past trainees have emerged as academic physicians developing independent clinical research programs often with external funding and with active investigator-initiated clinical trial efforts.

Public Health Relevance

This mentored career development program supports physician investigators to gain skills in cancer research and clinical therapeutics that emphasizes innovative treatments and use of genomics to select proper and individualized treatments for cancer patients, increasing the likelihood that such treatment will be effective.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA076917-17
Application #
8689940
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1997-09-30
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
17
Fiscal Year
2014
Total Cost
$631,819
Indirect Cost
$54,488
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Okoye, Christian C; Bucher, Jessica; Tatsuoka, Curtis et al. (2017) Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy. Head Neck 39:527-532
Caimi, Paolo F; Cooper, Brenda W; William, Basem M et al. (2017) Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. Oncotarget 8:79864-79875
Gutierrez, Daniel; Arbesman, Joshua (2016) Circadian Dysrhythmias, Physiological Aberrations, and the Link to Skin Cancer. Int J Mol Sci 17:
Eads, Jennifer R; Beumer, Jan H; Negrea, Lavinia et al. (2016) A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. Cancer Chemother Pharmacol 77:333-8
Malek, Ehsan; de Lima, Marcos; Letterio, John J et al. (2016) Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood Rev 30:341-8
de Blank, Peter M K; Fisher, Michael J; Lu, Lu et al. (2016) Impact of vision loss among survivors of childhood central nervous system astroglial tumors. Cancer 122:730-9
Gollamudi, Jahnavi; Parvani, Jenny G; Schiemann, William P et al. (2016) Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Manag Res 8:21-31
Telli, Melinda L; Jensen, Kristin C; Vinayak, Shaveta et al. (2015) Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol 33:1895-901
Peiris, Pubudu M; Abramowski, Aaron; Mcginnity, James et al. (2015) Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Res 75:1356-65
Goebel, Teresa E; Schiltz, Nicholas K; Woodside, Kenneth J et al. (2015) Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance. Clin Transplant 29:851-7

Showing the most recent 10 out of 58 publications